Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
JN.1.8.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
LV.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LV.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.54.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.54.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.7NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.30.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.30.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
KP.1.1.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KP.1.1.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.49.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.49.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.3.2.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-16719.1US
JN.3.2.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
LB.1.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LB.1.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.3.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-16719.1US
JN.3.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GE.1.2.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GE.1.2.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.58.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.58.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CH.1.1.18NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
CH.1.1.18NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.9NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FL.5.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.5.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HD.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HD.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HQ.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HQ.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FD.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FD.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.2.3.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.2.3.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GK.1.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GK.1.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EG.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.8NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EG.2.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.2.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FL.32NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.32NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FL.26.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.26.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EG.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used